NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Grove Biopharma

Grove Biopharma

Private
Chicago, IllinoisHealthcare & Life Scienceshttps://www.grovebiopharma.com/

Last Round

Series A

Apr 23, 2025

Total Funding Raised

$34.25M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Grove Biopharma is a biotechnology company that develops novel therapeutics targeting intracellular protein-protein interactions using its proprietary Bionic Biologics™ platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

biotechnologydrug discoveryprotein engineeringundruggable targetscomputational chemistryprecision medicinesynthetic therapeuticsproteomimeticsdrug designai drug discoveryintracellular targetspolymer chemistrybiopharmain silico drug designmolecular design

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Grove Biopharma Comparables

Compare Grove Biopharma with similar companies based on industry and business-model similarity.

Grove Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Libera Bio
75%
Dunad Therapeutics
73%
C4 Therapeutics
69%

Grove Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 23, 2025
GrantJul 15, 2023
SeedMay 10, 2021

Key People

Founding team and executive leadership

Paul A. Bertin

Co-Founder, President, And CTO

Founding Team

Geoffrey M. Duyk

Co-Founder, Chief Executive Officer

Founding Team

Laura Robinson

Chief Operating Officer

Executive Team

Grove Biopharma Investors

Notable investors and investment history

Grove Biopharma investors
InvestorRounds
U.S. Department of Health and Human ServicesGrant
DCVC BioSeries A
InVivium CapitalSeries A
Mansueto OfficeSeries A
Walder VenturesSeed, Series A
Skydeck CapitalSeed
Portal InnovationsSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 30, 2026

    Grew 50% QoQ, from 20 to 30 employees.

  • Aug 15, 2025

    Will participate in the Materials Biology symposium at the ACS Fall 2025 Scientific meeting.

Grove Biopharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Grove Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Grove Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersChicago, Illinois
Employee Range30
Year Founded2020
Last FundingApr 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.